Brief: Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension
30/10/2024 13:11
Oct 30 (Reuters) - Mineralys Therapeutics Inc MLYS.O :
* MINERALYS THERAPEUTICS COMPLETES ENROLLMENT AHEAD OF
SCHEDULE IN
LAUNCH-HTN, THE SECOND PIVOTAL TRIAL OF LORUNDROSTAT FOR THE
TREATMENT OF HYPERTENSION
* MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM LAUNCH-HTN
TRIAL
EXPECTED MID FIRST HALF OF 2025
Source text: ID:nGNX1N143L
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway